Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Food and Drug Administration, Understanding Investigational Drugs , April 2, 2019 GoodRx, Retatrutide for Weight Loss: Availability, Dosage, and More , June 25, 2026 Food and Drug Administration, Expanded Access, accessed June 29, 2026 Eli Lilly, Expanded Access | Compassionate Use | Clinical Trials , accessed June 29, 2026 WBUR | Here & Now, An extraordinary new obesity drug is still awaiting FDA approval
It lowers the cost of Rybelsus to as little as $10 per month with a maximum savings of $300 per month
Evidence: Grade B investigational, late-phase compound with promising controlled-trial data References: Phase 2/3 multi-receptor incretin agonist clinical-trial literature
Gastrointestinal tolerability remains the primary limitation in clinical practice
